BioNexus Gene Lab Corp
BGLC
查看详细走势图
4.150USD
+0.050+1.22%
收盘 12/24, 13:00（美东）报价延迟15分钟
7.46M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.22%
5天
+0.97%
1月
-5.90%
6月
+55.43%
今年开始到现在
+48.37%
1年
+70.78%
查看详细走势图
TradingKey BioNexus Gene Lab Corp股票评分
单位: USD 更新时间: 2025-12-24操作建议
BioNexus Gene Lab Corp当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名217/404位。机构持股占比非常高，中期看，股价处于下降通道。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
BioNexus Gene Lab Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
0
位分析师
--
评级
0.000
目标均价
0.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
BioNexus Gene Lab Corp亮点
亮点风险
BioNexus Gene Lab Corp. is a biotechnology company specializing in precision diagnostics and specialty chemical solutions. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.
业绩增长期
公司处于发展阶段，最新年度总收入9.51M美元
利润高增长
公司净利润处于行业前列，最新年度总收入9.51M美元
估值合理
公司最新PE估值-3.25，处于3年历史合理位
活跃度降低
近期活跃度降低，过去20天平均换手率-0.96
BioNexus Gene Lab Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
BioNexus Gene Lab Corp简介
BioNexus Gene Lab Corp. is a biotechnology company specializing in precision diagnostics and specialty chemical solutions. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.
公司代码BGLC
公司BioNexus Gene Lab Corp
CEOTan (Lee Su-Leng)
网址https://www.bionexusgenelab.com/
常见问题
BioNexus Gene Lab Corp(BGLC)的当前股价是多少？
BioNexus Gene Lab Corp(BGLC)的当前股价是 4.150。
BioNexus Gene Lab Corp的股票代码是什么？
BioNexus Gene Lab Corp的股票代码是BGLC。
BioNexus Gene Lab Corp股票的52周最高点是多少？
BioNexus Gene Lab Corp股票的52周最高点是15.600。
BioNexus Gene Lab Corp股票的52周最低点是多少？
BioNexus Gene Lab Corp股票的52周最低点是2.007。
BioNexus Gene Lab Corp的市值是多少？
BioNexus Gene Lab Corp的市值是7.46M。
BioNexus Gene Lab Corp的净利润是多少？
BioNexus Gene Lab Corp的净利润为-1.60M。
现在BioNexus Gene Lab Corp(BGLC)的股票是买入、持有还是卖出？
根据分析师评级，BioNexus Gene Lab Corp(BGLC)的总体评级为--，目标价格为--。
BioNexus Gene Lab Corp(BGLC)股票的每股收益（EPS TTM）是多少
BioNexus Gene Lab Corp(BGLC)股票的每股收益（EPS TTM）是-1.278。
相关品种
